Close Menu

NEW YORK ─ Harvard's Wyss Institute for Biologically Inspired Engineering announced Monday that it has licensed a low-cost, affinity-based electrochemical sensing platform, called eRapid, to Sydney-based iQ Group Global for COVID-19 diagnostic testing applications.

iQ Group Global, a consortium of Australian companies, will integrate the biomarker detection technology with its transistor technology to enable specific and sensitive SARS-CoV-2 testing, Wyss Institute said.

Financial and other terms of the agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.